Banco Comercial Portugues (BCP)
Euronext Lisbon · Portugal · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 1.090 |
|---|---|
| 52-week range | 0.748 – 1.243 |
| Return, 1 month / 3 months | −9.9% / +2.3% |
| Return, 1 year / 3 years | +46.5% / +336.2% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 42 |
| Volatility (1 year) | 26.3% |
| Worst drawdown (1 year) | -17.0% |
| Average daily value traded | 49.19M EUR |
| Dividend yield | 3.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Banco Comercial Portugues is a Portuguese banking group that serves individual customers, small businesses and larger companies. It offers current and savings accounts, mortgages, consumer credit, payment cards, insurance and investment products, along with corporate lending and treasury services. The bank operates a branch network in Portugal and runs its main retail brand under the Millennium name, and it also has banking operations in Poland and in several other international markets.
The shares are listed on the Euronext Lisbon in Portugal under the code BCP, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Banco Comercial Portugues (BCP) trades on the Euronext Lisbon in Portugal. It last closed at EUR 1.090 on 27 October 2026.
Its price-based Market X-Ray is 75 out of 100 (a strong price profile), ranking 3 of 36 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 46.5% and over the last three months it rose 2.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Lisbon
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 86 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 11.5% | ||
| From 52-week high | -10.8% | ||
| Momentum | 91 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 2.3% | ||
| 6-month return | 29.8% | ||
| 12-month return, skipping the last month | 62.6% | ||
| Stability (higher is calmer) | 57 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 26.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.0% | ||
| Liquidity | 100 · Strong | Trades actively. | |
| Average daily value traded | 49.19M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 18 · Weak | Dividend is small or irregular. | |
| Dividend yield | 3.2% | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −0.8% |
|---|---|
| 1 month | −9.9% |
| 3 months | +2.3% |
| 6 months | +29.8% |
| 1 year | +46.5% |
| 3 years | +336.2% |
| 5 years | +712.8% |
Signals
| 50-day / 200-day average | 1.143 / 0.978 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.027 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 1 Jun 2026 | EUR 0.0344 |
| 18 Jun 2025 | EUR 0.0300 |
| 19 Jun 2024 | EUR 0.0170 |
| 1 Jun 2022 | EUR 0.0009 |
| 7 Jun 2019 | EUR 0.0020 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Lisbon; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.